NAPLEX Quiz: Immunization And Prevention Programs

What this quiz covers

This quiz focuses on Immunization And Prevention Programs, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Administer PPSV23 now because she is older than 65 years and has not had a dose since age 62
2. Administer PCV20 now with no additional pneumococcal doses needed (correct answer)
3. Administer PCV13 now and schedule PPSV23 in 1 month
4. Defer pneumococcal vaccination because prior PPSV23 makes her ineligible for conjugate vaccines

Explanation: This question tests pneumococcal vaccination recommendations for older adults with prior PPSV23 receipt. The key patient-specific factor is the patient's age of 66 years and receipt of PPSV23 at age 62 due to chronic heart disease. Administering PCV20 now with no additional doses needed is the best choice because it provides broad protection for adults 65 years and older who previously received PPSV23 before age 65, without requiring further vaccination. Administering PPSV23 now is incorrect because repeat doses are not routinely recommended within 5 years, and PCV20 is preferred. Administering PCV13 now followed by PPSV23 is suboptimal per updated guidelines favoring PCV20 as a single dose in this scenario. A clinical pearl is that PCV20 simplifies pneumococcal vaccination by often eliminating the need for sequential dosing. Pharmacists should review immunization history to apply shared decision-making for pneumococcal vaccines in at-risk adults.

Question 2

1. Administer a single dose of an RSV vaccine indicated for adults aged 60 years and older (correct answer)
2. Administer RSV vaccine as a 2-dose series separated by 1 month
3. Administer RSV vaccine only if he also receives PPSV23 at the same visit
4. Defer RSV vaccination until age 80 because efficacy is inadequate at age 70

Explanation: This question tests RSV vaccination recommendations for older adults. The key patient-specific factor is the patient's age of 70 years and chronic kidney disease, increasing RSV risk. Administering a single dose of an RSV vaccine indicated for adults aged 60 years and older is the best choice based on shared decision-making for prevention of lower respiratory tract disease. Administering as a 2-dose series or only with PPSV23 is incorrect as RSV vaccines are single-dose and independent of other vaccines. Deferring until age 80 is suboptimal as efficacy supports use from age 60 in at-risk individuals. A transferable pearl is to use shared decision-making for RSV vaccination in adults 60+ considering comorbidities. Pharmacists should counsel on one-time dosing to simplify adult immunization schedules.

Question 3

1. These symptoms are common and typically self-limited; consider acetaminophen for comfort if needed (correct answer)
2. This represents anaphylaxis and she should avoid all future influenza vaccines
3. She is contagious with influenza from the vaccine and should isolate for 7 days
4. She should start oseltamivir prophylaxis because fever after vaccination indicates vaccine failure

Explanation: This question tests management of common adverse effects following inactivated influenza vaccination. The key patient-specific factor is the patient's low-grade fever and injection site soreness 2 days post-vaccination. Counseling that these symptoms are common and typically self-limited, with acetaminophen if needed, is the best approach as they represent normal immune responses resolving within days. Labeling this as anaphylaxis or advising avoidance of future vaccines is incorrect without systemic allergic symptoms. Suggesting isolation or oseltamivir is suboptimal as inactivated vaccines do not cause influenza infection. A clinical pearl is that local and systemic reactions are expected with many vaccines and rarely contraindicate future doses. Pharmacists should educate on expected side effects to improve vaccine acceptance and adherence.

Question 4

1. Administer MMR and varicella second doses now (age 4–6 years boosters) (correct answer)
2. Administer HPV vaccine series now because she is older than 4 years
3. Administer PPSV23 now because children should receive it at age 4
4. Defer all vaccines until age 11 because primary series is complete

Explanation: This question tests routine childhood immunization schedules at age 4–6 years. The key patient-specific factor is the patient's age of 4 years with only one dose each of MMR and varicella. Administering MMR and varicella second doses now is the best choice as they are recommended boosters at age 4–6 years to ensure long-term immunity. Administering HPV now is incorrect because it is routinely started at age 11–12 years, not at 4 years. Administering PPSV23 or deferring all vaccines until age 11 is suboptimal as healthy children do not need PPSV23, and boosters are due now. A transferable pearl is that the 4–6 year visit completes many childhood series with boosters. Pharmacists should align recommendations with ACIP schedules to optimize protection during school entry.

Question 5

1. Administer MenACWY booster dose now (correct answer)
2. Administer meningococcal B (MenB) vaccine now as a required routine vaccine for all 19-year-olds
3. Administer Tdap now and then repeat every 5 years
4. No vaccines are indicated until age 50 because childhood series is complete

Explanation: This question tests knowledge of adolescent catch-up immunization schedules, particularly for meningococcal vaccines. The key patient-specific factor is the patient's age of 19 years and receipt of only one MenACWY dose at age 11 without a booster. Administering the MenACWY booster dose now is the best choice because adolescents require a booster at age 16 or as soon as possible thereafter if missed to maintain protection against meningococcal disease. Administering MenB now is incorrect because it is not routinely required for all 19-year-olds but rather based on shared clinical decision-making. Administering Tdap now and repeating every 5 years is suboptimal because Tdap is a one-time adolescent dose with Td boosters every 10 years, and no booster is due yet. A key clinical pearl is that delays in vaccination schedules do not require restarting series; instead, resume where left off. Pharmacists should use immunization information systems to verify records and recommend catch-up doses accordingly.

Question 6

1. Administer MMR, varicella, and first dose of hepatitis A vaccine now (correct answer)
2. Administer HPV vaccine now to prevent future cervical cancer
3. Administer MenACWY now because it is routinely given at 12 months
4. Defer live vaccines until age 4 years to reduce fever risk

Explanation: This question tests knowledge of the recommended pediatric immunization schedule according to CDC guidelines for a 12-month-old child. The key patient-specific factors are the child's age of 12 months, healthy medical history with no allergies or medications, and incomplete vaccination status missing MMR, varicella, and hepatitis A vaccines. Administering MMR, varicella, and the first dose of hepatitis A vaccine now is the best recommendation because these are routinely indicated at 12-15 months for MMR and varicella, and 12-23 months for hepatitis A, to provide timely protection against these preventable diseases. Administering HPV vaccine now is incorrect because HPV vaccination is recommended starting at age 11-12 years, not at 12 months, and is not indicated for this infant to prevent future cervical cancer at this time; similarly, MenACWY is routinely given at 11-12 years, not at 12 months, making it inappropriate for this visit. Deferring live vaccines until age 4 years is suboptimal and incorrect as there is no evidence-based reason to delay MMR and varicella in a healthy child, and postponing increases the risk of disease exposure during vulnerable early childhood years. A key clinical pearl is to always consult the most current CDC immunization schedule to ensure age-appropriate vaccinations and catch-up doses. Pharmacists should prioritize patient-specific factors like age and prior immunizations when making recommendations to optimize protection and adherence.

Question 7

1. Use of systemic high-dose corticosteroids is a contraindication to live oral typhoid vaccine (correct answer)
2. Use of mesalamine is a contraindication to all travel vaccines
3. Departure in 10 days is a contraindication to any typhoid vaccination
4. History of inflammatory bowel disease is a contraindication to inactivated vaccines

Explanation: This question tests contraindications for live oral typhoid vaccine in travelers. The key patient-specific factor is the patient's use of high-dose prednisone for ulcerative colitis. Assessing use of systemic high-dose corticosteroids is crucial because they contraindicate live oral typhoid vaccine due to immunosuppression risks. Use of mesalamine, departure in 10 days, or history of IBD are not contraindications; inactivated typhoid vaccine can be used instead. These factors allow alternative vaccination options for travel protection. A clinical pearl is to prefer inactivated vaccines in immunocompromised travelers. Pharmacists should evaluate immunosuppression and travel timeline to select appropriate vaccine formulations.

Question 8

1. Start HPV vaccine series now (correct answer)
2. Administer MenACWY booster now because it is due 2 years after the first dose
3. Administer PPSV23 now because males should receive it at age 13
4. Administer MMR now because it is routinely repeated at age 13

Explanation: This question tests routine adolescent immunization recommendations. The key patient-specific factor is the patient's age of 13 years with no prior HPV vaccines. Starting the HPV vaccine series now is the best choice as it is recommended at age 11–12, with catch-up acceptable at 13 for cancer prevention. Administering MenACWY booster now is incorrect because it is due at 16, not 13. Administering PPSV23 or MMR repeat is suboptimal as they are not routine for healthy 13-year-old males. A transferable pearl is that adolescent visits are key for initiating multi-dose series like HPV. Pharmacists should prioritize HPV vaccination in teens using a catch-up framework to maximize uptake.

Question 9

1. Administer HPV vaccine as a 2-dose series at 0 and 6 months because she is under 30 years old
2. Administer HPV vaccine as a 3-dose series at 0, 1–2, and 6 months (correct answer)
3. Do not vaccinate because HPV vaccine is only recommended through age 26 years
4. Administer HPV vaccine 1 dose now and no further doses are needed because she is an adult

Explanation: This question tests knowledge of HPV vaccine catch-up schedules for adults. The key patient-specific factor is that this 28-year-old female has never received HPV vaccine and is within the approved age range for vaccination. The correct answer (B) is best because adults initiating HPV vaccination at age 15 or older require a 3-dose series at 0, 1-2, and 6 months, regardless of age. The 2-dose schedule (A) only applies to those starting the series before age 15. Option C is incorrect as HPV vaccine can be given through age 45 based on shared clinical decision-making. Single-dose regimens (D) are not approved for HPV vaccine. The clinical pearl is that HPV vaccine dosing depends on age at series initiation, not current age, with those starting at ≥15 years always requiring 3 doses for optimal immunogenicity.

Question 10

1. Administer MenACWY 1 dose now (college entry booster) (correct answer)
2. Administer MenB (meningococcal B) 2-dose series now because MenACWY is complete
3. Administer Tdap now because it has been 8 years since the last dose
4. Administer hepatitis B vaccine 1 dose now because titers are unknown

Explanation: This question tests knowledge of meningococcal vaccine recommendations for college-aged students. The key patient-specific factor is that this 19-year-old is entering college and received only one dose of MenACWY at age 11 without the recommended booster. The correct answer (A) is best because ACIP recommends a MenACWY booster dose at age 16 years or before college entry for those who received their first dose before age 16. MenB vaccine (B) is not routinely recommended for all college students unless there's an outbreak or specific risk factors. Tdap (C) is not due until 10 years after the last dose (she's only at 8 years). Hepatitis B (D) is unnecessary as she completed the series as an infant, and routine titer checking is not recommended for immunocompetent individuals. The clinical pearl is that college students living in dormitories are at increased risk for meningococcal disease, making the MenACWY booster a priority vaccination before college entry.

Question 11

1. History of anaphylaxis to gelatin (correct answer)
2. Use of cetirizine (antihistamine) within the last 24 hours
3. Prior receipt of Tdap more than 10 years ago
4. Seasonal allergic rhinitis

Explanation: This question tests knowledge of vaccine contraindications and precautions. The key patient-specific factor is this patient's history of anaphylaxis to gelatin requiring epinephrine. The correct answer (A) is best because varicella vaccine contains gelatin as a stabilizer, and a history of anaphylaxis to gelatin is an absolute contraindication to varicella vaccination. Antihistamine use (B) is not a contraindication to any vaccine. Prior Tdap receipt (C) is irrelevant to varicella vaccine administration. Seasonal allergic rhinitis (D) is not a contraindication to vaccination. The clinical framework is that anaphylaxis to a vaccine component is an absolute contraindication, while minor illnesses or allergies unrelated to vaccine components are not contraindications. For patients with gelatin allergy, alternative strategies like serologic testing for immunity should be considered.

Question 12

1. History of Guillain-Barré syndrome within 6 weeks of a prior influenza vaccine
2. Severe allergic reaction (anaphylaxis) after a previous influenza vaccine dose (correct answer)
3. Egg allergy of any severity
4. Receipt of Tdap within the past 10 years

Explanation: This question tests understanding of vaccine contraindications versus precautions. The key patient-specific factor is that this patient experienced anaphylaxis (hives and lip swelling requiring epinephrine) after a previous influenza vaccine. The correct answer (B) is best because severe allergic reaction/anaphylaxis to a previous dose of any vaccine is an absolute contraindication to future doses of that vaccine. Guillain-Barré syndrome (A) within 6 weeks is a precaution, not a contraindication. Egg allergy (C) is no longer a contraindication to influenza vaccine, as egg-free formulations exist and most egg-allergic patients can safely receive standard vaccines. Prior Tdap (D) is irrelevant to influenza vaccination. The clinical framework is distinguishing contraindications (anaphylaxis to vaccine/component) from precautions (GBS history), with true anaphylaxis being the only absolute contraindication among the choices.

Question 13

1. Administer Tdap now (or Td if Tdap not available) because last tetanus-containing vaccine was >10 years ago (correct answer)
2. Administer tetanus immune globulin only because boosters are not used in adults
3. No tetanus-containing vaccine is needed because the wound is clean
4. Administer DTaP now because it provides stronger tetanus protection in adults

Explanation: This question tests tetanus prophylaxis for wound management in adults. The key patient-specific factor is the patient's last tetanus-containing vaccine 12 years ago and a clean minor wound. Administering Tdap now (or Td if unavailable) is the best choice because boosters are recommended for clean wounds if more than 10 years since last dose. Administering tetanus immune globulin only or no vaccine is incorrect as active immunization is needed for long-term protection. Administering DTaP is suboptimal as it is not indicated for adults. A clinical pearl is to use the >10-year rule for clean wounds and >5-year for dirty in tetanus prophylaxis. Pharmacists should assess wound type and vaccination history to guide appropriate booster selection.

Question 14

1. History of severe allergic reaction to a vaccine component such as polyethylene glycol (correct answer)
2. Receipt of influenza vaccine in the same season
3. Age older than 40 years
4. Time since primary series longer than 2 years

Explanation: This question tests contraindications for COVID-19 mRNA vaccines. The key patient-specific factor is the patient's history of anaphylaxis to polyethylene glycol (PEG). Assessing severe allergic reaction to a vaccine component like PEG is crucial because it is a contraindication for PEG-containing mRNA vaccines due to anaphylaxis risk. Receipt of influenza vaccine, age over 40, or time since primary series are not contraindications for boosters. These factors do not impact eligibility for updated COVID-19 vaccination. A clinical pearl is to screen for excipient allergies before mRNA vaccines and consider alternatives like protein-based options. Pharmacists should use a risk-assessment framework to ensure safe COVID-19 vaccine administration.

Question 15

1. Administer PCV20 (pneumococcal conjugate vaccine) 1 dose now (correct answer)
2. Administer PPSV23 1 dose now because it has been 1 year since the last PPSV23
3. Administer PCV15 now and repeat PPSV23 in 8 weeks
4. No pneumococcal vaccine is indicated because PPSV23 was given after age 65

Explanation: This question tests knowledge of pneumococcal vaccination recommendations for adults 65 years and older. The key patient-specific factor is that this 67-year-old has COPD and received only PPSV23 at age 66 without any prior conjugate vaccine. The correct answer (A) is best because current ACIP guidelines recommend PCV20 alone OR PCV15 followed by PPSV23 for pneumococcal vaccine-naïve adults ≥65 years; since he already received PPSV23, giving PCV20 completes his pneumococcal series. Repeating PPSV23 (B) is incorrect as the minimum interval between PPSV23 doses is 5 years. PCV15 followed by another PPSV23 (C) is not the recommended sequence when PPSV23 was already given. Option D is wrong because all adults ≥65 need conjugate vaccine coverage regardless of prior PPSV23. The clinical pearl is that PCV20 provides broader serotype coverage than PCV15 and eliminates the need for subsequent PPSV23, simplifying the vaccination schedule for older adults.

Question 16

1. Restart the HPV series from dose 1 because more than 5 years have passed
2. Administer 2 additional HPV doses to complete a 3-dose series (since series started at age 15) (correct answer)
3. Administer 1 additional HPV dose only to complete a 2-dose series
4. Defer HPV vaccination because it is not recommended after age 21

Explanation: This question tests catch-up scheduling for HPV vaccination. The key patient-specific factor is the patient's age of 22 years with one HPV dose at age 15. Administering 2 additional HPV doses to complete a 3-dose series is the best choice because series initiated at age 15 or older require 3 doses for full protection. Restarting the series or administering only 1 additional dose is incorrect as prior doses count and younger initiations allow 2 doses. Deferring after age 21 is suboptimal as catch-up is recommended through age 26. A transferable pearl is that HPV series do not restart after delays; resume with remaining doses. Pharmacists should apply age-at-initiation rules to determine dosing needs in catch-up scenarios.

Question 17

1. Initiate a smoking cessation plan with counseling and offer nicotine replacement therapy options (correct answer)
2. Recommend daily aspirin 325 mg for primary prevention of cardiovascular disease
3. Recommend starting a proton pump inhibitor to prevent stress ulcers
4. Recommend routine antibiotic prophylaxis during flu season to prevent infection

Explanation: This question tests knowledge of preventive health measures in pharmacy practice. The key patient-specific factor is that this 45-year-old has a 20 pack-year smoking history and expresses interest in quitting. The correct answer (A) is best because smoking cessation is the single most impactful preventive measure for this patient, reducing risks of cardiovascular disease, cancer, and pulmonary disease. Aspirin 325mg (B) is not routinely recommended for primary prevention in this age group without calculating ASCVD risk. Proton pump inhibitors (C) for stress ulcer prophylaxis are only indicated in critically ill patients. Routine antibiotic prophylaxis (D) is inappropriate and promotes resistance. The clinical framework is that pharmacists should prioritize evidence-based preventive measures, with smoking cessation providing the greatest health benefit for current smokers. Pharmacists can provide tobacco cessation counseling and recommend FDA-approved cessation aids.

Question 18

1. History of severe allergic reaction (e.g., anaphylaxis) to a prior influenza vaccine dose or component (correct answer)
2. History of allergic rhinitis
3. Age younger than 50 years
4. Use of intranasal corticosteroids

Explanation: This question tests contraindications for influenza vaccination following prior reactions. The key patient-specific factor is the patient's history of anaphylaxis-like symptoms after a previous influenza vaccine dose. Assessing history of severe allergic reaction to a prior dose or component is crucial because it contraindicates further administration of similar vaccines due to recurrence risk. History of allergic rhinitis or use of intranasal corticosteroids are not contraindications and do not preclude vaccination. Age younger than 50 years is irrelevant for adult influenza vaccine eligibility. A clinical pearl is to distinguish true anaphylaxis from other reactions for future vaccine decisions. Pharmacists should document reactions and consider allergist consultation for unclear cases.

Question 19

1. Administer live zoster vaccine (ZVL) 1 dose now because it provides rapid protection
2. Administer recombinant zoster vaccine (RZV) 2-dose series starting today (correct answer)
3. Defer all zoster vaccination until prednisone is discontinued for at least 6 months
4. Administer varicella vaccine 2-dose series instead of zoster vaccine due to immunosuppression

Explanation: This question tests understanding of zoster vaccine selection in immunocompromised patients. The key patient-specific factor is that this 52-year-old has rheumatoid arthritis treated with tofacitinib (a JAK inhibitor) and prednisone, making her moderately immunocompromised. The correct answer (B) is best because recombinant zoster vaccine (RZV/Shingrix) is preferred for immunocompromised patients as it's non-live and provides robust protection. Live zoster vaccine (A) is contraindicated in immunosuppressed patients. Deferring vaccination (C) is inappropriate as these patients are at higher risk for shingles and RZV can be safely given. Varicella vaccine (D) is for primary prevention of chickenpox, not shingles, and is also live. The clinical pearl is that RZV is the only zoster vaccine option for immunocompromised patients and should be given as a 2-dose series (0 and 2-6 months) regardless of prior varicella or zoster history.

Question 20

1. Administer DTaP now and schedule the remaining doses per catch-up schedule
2. Restart the entire DTaP series from dose 1 because of the long interval
3. Administer Tdap now because children older than 7 years must receive Tdap instead of DTaP (correct answer)
4. Defer tetanus-containing vaccines until age 11 because he already received 3 infant doses

Explanation: This question tests catch-up immunization schedules for tetanus-containing vaccines in children. The key patient-specific factor is the patient's age of 7 years and incomplete DTaP series with only 3 doses received in infancy. Administering Tdap now is the best choice because children aged 7 years and older should receive Tdap instead of DTaP to complete the series, providing pertussis protection. Administering DTaP now is incorrect as it is not approved for use in children 7 years and older. Restarting the series or deferring until age 11 is suboptimal because interruptions do not require restarting, and catch-up should resume promptly. A transferable pearl is to use age-appropriate formulations like Tdap for catch-up in older children. Pharmacists should follow ACIP catch-up schedules to ensure series completion without unnecessary delays.